Thus, despite the successful implementation of targeted NGS panels in routine clinical diagnostics of NSCLC [71], this method is still affected by challenges with respect to the detection of MET amplification and prediction of response to TKI treatment. This evidence concerns the gene MET and non-small cell lung carcinoma.